# Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons

**Authors:** Hoang Kieu Chi Ngo, Hoang Le, Samuel J. Ayer, Grace F. Crotty, Michael A. Schwarzschild, Rachit Bakshi

PMC · DOI: 10.21203/rs.3.rs-4076333/v1 · Research Square · 2024-03-21

## TL;DR

Short-term LPS treatment in mice with a Parkinson's-related LRRK2 mutation causes astrocyte activation but not neuron loss, and caffeine reduces this activation.

## Contribution

Short-term LPS treatment in LRRK2 G2019S knock-in mice models astrocyte activation without neuron loss, and caffeine attenuates this effect.

## Key findings

- LPS treatment increased astrocyte activation in LRRK2 G2019S KI mice but not neuron loss.
- Caffeine reduced LPS-induced astrocyte activation in LRRK2 G2019S KI mice.
- LPS caused incomplete recovery from weight loss in LRRK2 G2019S KI mice.

## Abstract

The G2019S mutation of LRRK2, which enhances kinase activity of the protein, confers a substantial risk of developing Parkinson’s disease (PD). However, the mutation demonstrates incomplete penetrance, suggesting the involvement of other genetic or environmental modulating factors. Here, we investigated whether LRRK2 G2019S knock-in (KI) mice treated with the inflammogen lipopolysaccharide (LPS) could model LRRK2 PD.

We found that short-term (2 weeks) treatment with LPS did not result in the loss of dopaminergic neurons in either LRRK2 G2019S KI or wild-type (WT) mice. Compared with WT mice, LRRK2 G2019S-KI mice showed incomplete recovery from LPS-induced weight loss. In LRRK2 G2019S KI mice, LPS treatment led to upregulated phosphorylation of LRRK2 at the autophosphorylation site Serine 1292, which is known as a direct readout of LRRK2 kinase activity. LPS treatment caused a greater increase in the activated astrocyte marker glial fibrillary acidic protein (GFAP) in the striatum and substantia nigra of LRRK2 G2019S mice than in those of WT mice. The administration of caffeine, which was recently identified as a biomarker of resistance to developing PD in individuals with LRRK2 mutations, attenuated LPS-induced astrocyte activation specifically in LRRK2 G2019S KI mice.

Our findings suggest that 2 weeks of exposure to LPS is not sufficient to cause dopaminergic neuronal loss in LRRK2 G2019S KI mice but rather results in increased astrocyte activation, which can be ameliorated by caffeine.

## Linked entities

- **Genes:** LRRK2 (leucine rich repeat kinase 2) [NCBI Gene 120892]
- **Proteins:** GFAP (glial fibrillary acidic protein)
- **Chemicals:** caffeine (PubChem CID 2519)
- **Diseases:** Parkinson’s disease (MONDO:0005180), PD (MONDO:0005180)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, LRRK2 (leucine rich repeat kinase 2) [NCBI Gene 120892] {aka AURA17, DARDARIN, PARK8, RIPK7, ROCO2}
- **Diseases:** weight loss (MESH:D015431), PD (MESH:D010300), dopaminergic neuronal loss (MESH:D009410)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** G2019S

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10984011/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10984011/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC10984011/full.md

---
Source: https://tomesphere.com/paper/PMC10984011